-transparent.png){kind=logo}
In eight patients a sparteine-test was carried out immediately before and after 1 week of treatment with quinidine 600-800 mg day-1. Before treatment one patient was classified as a poor metaboliser (metabolic ratio: greater than or equal to 20), and seven patients as extensive metabolisers. During quinidine treatment, the formation of sparteine metabolites (2- and 5-dehydrosparteine) was practically abolished. Patients initially classified as extensive metabolisers thus exhibited the phenotype of poor metabolisers during quinidine treatment.
Related Publications
R Brinn, and
K Brøsen, and
L F Gram, and
T Haghfelt, and
S V Otton
August 1986,
British journal of clinical pharmacology,
R Brinn, and
K Brøsen, and
L F Gram, and
T Haghfelt, and
S V Otton
January 1995,
European journal of clinical pharmacology,
R Brinn, and
K Brøsen, and
L F Gram, and
T Haghfelt, and
S V Otton
February 1990,
British journal of clinical pharmacology,
R Brinn, and
K Brøsen, and
L F Gram, and
T Haghfelt, and
S V Otton
January 1988,
Drug metabolism and disposition: the biological fate of chemicals,
R Brinn, and
K Brøsen, and
L F Gram, and
T Haghfelt, and
S V Otton
March 1990,
British journal of clinical pharmacology,
R Brinn, and
K Brøsen, and
L F Gram, and
T Haghfelt, and
S V Otton
November 1985,
Acta pharmacologica et toxicologica,
R Brinn, and
K Brøsen, and
L F Gram, and
T Haghfelt, and
S V Otton
November 1988,
Klinische Wochenschrift,
R Brinn, and
K Brøsen, and
L F Gram, and
T Haghfelt, and
S V Otton
March 1948,
Federation proceedings,
R Brinn, and
K Brøsen, and
L F Gram, and
T Haghfelt, and
S V Otton
January 1989,
European journal of clinical pharmacology,
R Brinn, and
K Brøsen, and
L F Gram, and
T Haghfelt, and
S V Otton
June 1986,
British journal of clinical pharmacology,
